FLT3 and acute myeloid leukemia: Insights into the role of FLT-3 biology and pathophysiology have ushered in new paradigms for treatments tailored to heterogeneous AML subtypes with resulting improvements in survival rates, particularly for patients harboring FLT mutations [9,16].